EcoDrugPlus

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSCGOG00000001511
Gene Symbol: LOC115017719
3 Cross references
270 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-2-Like

Ensembl ID : ENSCGOG00000021903
Gene Symbol: LOC115022139
3 Cross references
205 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSCGOG00000024218
Gene Symbol: LOC115019172
3 Cross references
197 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-233-Like

Ensembl ID : ENSCGOG00000000490
Gene Symbol: LOC115021035
3 Cross references
215 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3-Like

Ensembl ID : ENSCGOG00000015806
Gene Symbol: LOC115005036
3 Cross references
230 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSCGOG00000013610
Gene Symbol: SLC10A2
3 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSCGOG00000021297
Gene Symbol: SLC18A2
3 Cross references
174 Possible Orthologues:

Solute Carrier Family 22 Member 6-Like

Ensembl ID : ENSCGOG00000008361
Gene Symbol: LOC115018929
3 Cross references
360 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSCGOG00000017841
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSCGOG00000012948
Gene Symbol: SLC5A2
3 Cross references
199 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSCGOG00000023351
Gene Symbol: SLC6A1
3 Cross references
208 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSCGOG00000021954
Gene Symbol: SLC6A2
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).